Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Alembic Pharma gets USFDA nod for generic influenza treatment drug
Alembic Pharmaceuticals has secured USFDA approval for its generic oseltamivir phosphate oral suspension, a key treatment for influenza. This development offers a more accessible option for patients aged two weeks and above suffering from acute, uncomplicated flu. The approval marks a significant step in providing affordable alternatives to the reference drug, Tamiflu, potentially impacting a market valued at an estimated USD 27 million.
Alembic gets USFDA nod for generic levothyroxine sodium tablets
Alembic Pharmaceuticals has secured final approval from the US health regulator for its generic levothyroxine sodium tablets. This medication is used as a replacement therapy for hypothyroidism. The approval covers multiple strengths of the tablets. This development is significant for patients seeking affordable treatment options. The market for these tablets is substantial.